Lin Elizabeth Yeu 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
Tarsus (TARS) CMO Lin Yeu Sells 1,144 Shares
What Happened
- Lin Elizabeth Yeu, Chief Medical Officer of Tarsus Pharmaceuticals, reported three open-market sales (code S) totaling 1,144 shares: 375 shares at $69.42 on 2026-03-17 ($26,033); 379 shares at $68.71 on 2026-03-18 ($26,041); and 390 shares at $67.00 on 2026-03-19 ($26,130). Aggregate proceeds were approximately $78,204. These were sales (dispositions), not purchases.
Key Details
- Transaction dates & prices:
- 2026-03-17: 375 shares @ $69.42 = $26,033
- 2026-03-18: 379 shares @ $68.71 = $26,041
- 2026-03-19: 390 shares @ $67.00 = $26,130
- Total: 1,144 shares; ~$78,204 proceeds.
- Shares owned after the transactions: not specified in the provided filing.
- Filing date: Form 4 filed 2026-03-19 (covers trades dated 2026-03-17–03-19).
- Footnote: Sales were sell-to-cover transactions to satisfy tax withholding on RSU vesting and were mandated by the issuer (not discretionary by the insider).
Context
- "Sell-to-cover" means shares were sold specifically to cover tax withholding tied to RSU settlement; this is a routine administrative transaction and not necessarily an indicator of the insider's view of the company. Purchases typically convey stronger signals than mandatory sell-to-cover sales.
Insider Transaction Report
Form 4
Lin Elizabeth Yeu
Chief Medical Officer
Transactions
- Sale
Common Stock
[F1]2026-03-17$69.42/sh−375$26,033→ 24,077 total - Sale
Common Stock
[F1]2026-03-18$68.71/sh−379$26,041→ 23,698 total - Sale
Common Stock
[F1]2026-03-19$67.00/sh−390$26,130→ 23,308 total
Holdings
- 6,360(indirect: By Spouse)
Common Stock
- 12,040(indirect: By 401(k))
Common Stock
Footnotes (1)
- [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact|2026-03-19